salmeterol beta2adrenergic receptor beta2ar agonist commonly used treatment asthma chronic obstructive pulmonary disease differs low intrinisic efficacy especially compared available betaagonist formoterol receptor desensitization described chronic use effect related stabilization altered receptor states extreme hydrophobicity quasiirreversible binding salmeterol rendered studies examining mechanisms mediates receptor desensitization internalization difficult determined capacity salmeterol induce beta2ar endocytosis g receptor kinase phosphorylation degradation translocation hek293 cells compared agonists varying intrinsic efficacies despite stimulating phosphorylation ser355356 NUMBER min NUMBER h extent similar observed agonists high intrinsic efficacy epinephrine formoterol salmeterol did induce significant beta2ar internalization degradation incapable stimulating translocation enhanced green fluorescent chimera cell surface receptor endocytosis rescued overexpression data indicate salmeterol binding induces active receptor state unable recruit undergo significant endocytosis degradation despite stimulating considerable phosphorylation defects components receptor desensitization important determinants sustained bronchodilation chronic use long acting beta agonists long acting regulation beta agonists beta agonists high affinity regulation protein coupled grk site beta arrestin2 grk mediated protein beta arrestin2 egfp beta arrestin2 salmeterol induced egfp beta arrestin2 beta arrestin grk site salmeterol induced